X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Glenmark Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs GLENMARK PHARMA - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

GLENMARK PHARMA 
   Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH GLENMARK PHARMA PANACEA BIOTECH/
GLENMARK PHARMA
 
P/E (TTM) x -6.3 19.8 - View Chart
P/BV x 1.9 3.5 54.3% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 PANACEA BIOTECH   GLENMARK PHARMA
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
GLENMARK PHARMA
Mar-18
PANACEA BIOTECH/
GLENMARK PHARMA
5-Yr Chart
Click to enlarge
High Rs149930 16.0%   
Low Rs82517 15.9%   
Sales per share (Unadj.) Rs84.1322.6 26.1%  
Earnings per share (Unadj.) Rs-18.328.5 -64.3%  
Cash flow per share (Unadj.) Rs-6.739.2 -17.1%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.3 0.0%  
Book value per share (Unadj.) Rs83.7183.0 45.7%  
Shares outstanding (eoy) m61.25282.17 21.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.42.2 61.2%   
Avg P/E ratio x-6.325.4 -24.8%  
P/CF ratio (eoy) x-17.218.5 -93.4%  
Price / Book Value ratio x1.44.0 34.9%  
Dividend payout %07.0 0.0%   
Avg Mkt Cap Rs m7,074204,206 3.5%   
No. of employees `0002.813.7 20.0%   
Total wages/salary Rs m1,44918,718 7.7%   
Avg. sales/employee Rs Th1,874.16,636.8 28.2%   
Avg. wages/employee Rs Th527.01,364.7 38.6%   
Avg. net profit/employee Rs Th-407.7586.1 -69.6%   
INCOME DATA
Net Sales Rs m5,15491,031 5.7%  
Other income Rs m100914 10.9%   
Total revenues Rs m5,25491,945 5.7%   
Gross profit Rs m-76616,154 -4.7%  
Depreciation Rs m7113,019 23.6%   
Interest Rs m1,5032,856 52.6%   
Profit before tax Rs m-2,88111,193 -25.7%   
Minority Interest Rs m110-   
Prior Period Items Rs m-60-   
Extraordinary Inc (Exp) Rs m1,7710-   
Tax Rs m173,155 0.5%   
Profit after tax Rs m-1,1218,039 -13.9%  
Gross profit margin %-14.917.7 -83.8%  
Effective tax rate %-0.628.2 -2.1%   
Net profit margin %-21.88.8 -246.4%  
BALANCE SHEET DATA
Current assets Rs m3,81069,887 5.5%   
Current liabilities Rs m8,36532,879 25.4%   
Net working cap to sales %-88.440.7 -217.4%  
Current ratio x0.52.1 21.4%  
Inventory Days Days15681 191.2%  
Debtors Days Days6793 71.9%  
Net fixed assets Rs m14,48028,892 50.1%   
Share capital Rs m61282 21.7%   
"Free" reserves Rs m90351,353 1.8%   
Net worth Rs m5,12751,635 9.9%   
Long term debt Rs m5,83241,418 14.1%   
Total assets Rs m19,433125,954 15.4%  
Interest coverage x-0.94.9 -18.6%   
Debt to equity ratio x1.10.8 141.8%  
Sales to assets ratio x0.30.7 36.7%   
Return on assets %2.08.6 22.7%  
Return on equity %-21.915.6 -140.5%  
Return on capital %3.615.1 24.1%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53936,317 4.2%   
Fx outflow Rs m9429,720 9.7%   
Net fx Rs m59726,598 2.2%   
CASH FLOW
From Operations Rs m59916,481 3.6%  
From Investments Rs m-438-10,133 4.3%  
From Financial Activity Rs m-303-4,685 6.5%  
Net Cashflow Rs m-1411,770 -8.0%  

Share Holding

Indian Promoters % 74.5 48.3 154.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.6 6.9 8.7%  
FIIs % 1.3 34.4 3.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.5 224.8%  
Shareholders   10,259 56,727 18.1%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare PANACEA BIOTECH With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades 370 Points Up; Hero MotoCorp & Tata Motors Gain Over 5%(12:30 pm)

Stock markets in India are presently trading higher following the outcome of assembly polls announced on Tuesday.

Related Views on News

PANACEA BIOTECH Announces Quarterly Results (2QFY19); Net Profit Down 1631.6% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, PANACEA BIOTECH has posted a net profit of Rs 975 m (down 1631.6% YoY). Sales on the other hand came in at Rs 1 bn (down 22.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Dec 12, 2018 02:47 PM

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 5-YR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS